Chilean Fish Farming Taking an Important Innovative Step to Control Salmon Rickettsial Septicaemia (SRS) Syndrome
First attenuated live vaccine against SRS*, ALPHA JECT LiVac® SRS, has been approved by the Chilean authorities and is available for customers in Chile.
The vaccine was developed to fight the SRS disease that causes significant costs to the Chilean fish farming industry.
PUERTO MONTT, CHILE - PHARMAQ's vaccine ALPHA JECT LiVac® SRS received a provisional marketing authorisation (PMA number 2320-BP) from the Chilean authority, Servicio Agrícola y Ganadero de Chile (SAG).
"Our innovative drive is based on the aquaculture industry's need to produce safe and healthy seafood. We are confident that this ground-breaking vaccine will be an important tool to help fight SRS. This is a highly requested product by the industry and will help achieve more predictable and reliable fish production,” says the President of PHARMAQ Morten Kr. Nordstad.
The approval from the Chilean authority (SAG) to sell the attenuated live vaccine is a major technology milestone for the fish farming industry and for PHARMAQ. Behind this product are many years of research, development and documentation to ensure a high quality product that provides a high level of protection as well as being safe for the fish and the environment.
*Salmon Rickettsial Septicaemia (SRS) or Piscirickettsiosis is considered to be the most important disease problem in the Chilean salmon farming industry. The disease is caused by the bacterium Piscirickettsia salmonis, generating a severe disease that has caused major economic losses in the aquaculture industry since its appearance in 1989. The disease is affecting all three species farmed in Chile: Atlantic salmon, rainbow trout and Coho salmon.
PHARMAQ, a part of Zoetis, is the global leader in vaccines and innovation for aquaculture. The company provides environmentally sound, safe and efficacious health products to the global aquaculture industry through targeted research and the commitment of dedicated people. Production facilities, administration and research and development activities are based in Norway with subsidiaries in Chile, United Kingdom, Vietnam, Turkey, Spain, Panama and Hong Kong. PHARMAQ has approximately 200 employees. The company's products are marketed in Europe, North and South America, and Asia. For further information, visit the company's website at www.pharmaq.com
Bernd Wrege, Managing Director PHARMAQ, Chile
+56 9 98713240